Similar articles

• Tuberculosis preventive therapy in HIV-infected persons: feasibility issues in developing countries.

  Hawken MP, Muhindi DW. Hawken MP, et al. Int J Tuberc Lung Dis. 1999 Aug;3(8):646-50. Int J Tuberc Lung Dis. 1999. PMID: 10460096 Review.
• [Primary chemoprevention of tuberculosis in HIV-infected patients in non-industrialized countries].

  Anglaret X, Dabis F, Batungwanayo J, Perronne C, Taelman H, Bonard D, Sylla-Koko F, Leroy V, Van de Perre P, Vildé JL, Salamon R. Anglaret X, et al. Sante. 1997 Mar-Apr;7(2):89-94. Sante. 1997. PMID: 9273126 Review. French.
• Short-term tuberculosis prophylaxis is effective in persons with HIV.

  Gordin F. Gordin F. Am Fam Physician. 1998 Sep 15;58(4):948. Am Fam Physician. 1998. PMID: 9767729 No abstract available.
• Isoniazid preventive therapy for HIV-infected people: evidence to support implementation.

  Eldred LJ, Churchyard G, Durovni B, Godfrey-Faussett P, Grant AD, Getahun H, Chaisson RE. Eldred LJ, et al. AIDS. 2010 Nov;24 Suppl 5:S1-3. doi: 10.1097/01.aids.0000391009.95149.ec. AIDS. 2010. PMID: 21079422 No abstract available.
• Risk factors for development of tuberculosis after isoniazid chemoprophylaxis in human immunodeficiency virus-infected patients.

  Casado JL, Moreno S, Fortún J, Antela A, Quereda C, Navas E, Moreno A, Dronda F. Casado JL, et al. Clin Infect Dis. 2002 Feb 1;34(3):386-9. doi: 10.1086/324746. Epub 2001 Dec 19. Clin Infect Dis. 2002. PMID: 11753825 Clinical Trial.